)
Mark Arundine
U.S. Head of Neuroscience & Ophthalmology, Corporate Business Development
Roche and Genentech
Mark Arundine is the U.S. Head of Neuroscience & Ophthalmology within Corporate Business Development at Roche/Genentech. Currently leads a US-based Business Development team responsible for identifying strategic external innovation with research stakeholders, in addition to managing the evaluation and execution of tailored partnerships. Mark has extensive experience with leading diligences and deals across multiple therapeutic areas and modalities, encompassing platforms to clinical-stage assets. In addition to his Business Development leadership, Mark has launched and managed multiple strategic collaborations in Alliance Management. Prior to joining Corporate Business Development, he served multiple roles in Global Product Strategy, Affiliate Medical Affairs, and Sales and Marketing across oncology and immunology therapeutic areas. Mark received his PhD in Physiology (Neuroscience) from the University of Toronto, MSc in Pathology (Neuroscience) from The University of Western Ontario, Canada and MBA from Rollins College, Orlando.
Sessions
-
24-Jun-2026Theater 2Genentech, a Member of the Roche Group
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}